Dyne Therapeutics (DYN) financial statements
Net income was -$446M.
Free cash flow was -$405M.
The diluted share count rose 1983% over the period (dilution).
Income statement
Fiscal years, from Dyne Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Research and development | $11M | $45M | $121M | $143M | $211M | $281M | $398M |
| Selling, general and admin | $3M | $13M | $29M | $28M | $31M | $62M | $70M |
| Operating income | -$14M | -$59M | -$150M | -$171M | -$242M | -$344M | -$468M |
| Income tax | — | — | — | — | $0 | $0 | $0 |
| Net income | -$15M | -$59M | -$149M | -$168M | -$236M | -$317M | -$446M |
| EPS (diluted) | -$6.08 | -$4.13 | -$2.93 | -$3.23 | -$3.95 | -$3.37 | -$3.47 |
| Diluted shares | 2M | 14M | 51M | — | — | — | — |
Balance sheet
Fiscal years, from Dyne Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $15M | $345M | $377M | $256M | $123M | $642M | $1.1B |
| Total current assets | $15M | $349M | $382M | $266M | $129M | $659M | $1.1B |
| Property, plant and equipment | $1M | $2M | $5M | $6M | $5M | $5M | $24M |
| Total assets | $16M | $353M | $426M | $306M | $165M | $691M | $1.2B |
| Total current liabilities | $2M | $11M | $29M | $28M | $51M | $42M | $51M |
| Total liabilities | $2M | $11M | $57M | $54M | $74M | $61M | $215M |
| Shareholders' equity | $14M | $342M | $368M | $252M | $91M | $630M | $972M |
| Net debt | -$15M | -$301M | -$201M | -$172M | -$122M | -$435M | -$893M |
Cash flow
Fiscal years, from Dyne Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12M | -$47M | -$120M | -$154M | -$188M | -$292M | -$403M |
| Capital spending | $2M | $1M | $4M | $3M | $729,000 | $2M | $2M |
| Free cash flow | -$13M | -$48M | -$123M | -$157M | -$189M | -$295M | -$405M |
| Stock-based compensation | $26,000 | $7M | $18M | $15M | $20M | $46M | $46M |
| Net borrowing | — | -$64,000 | — | — | $0 | $0 | $148M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for DYN.
Open DYN in InvestinglyQuestions
How much free cash flow does Dyne Therapeutics generate?
-$405M in fiscal 2025 (operating cash flow minus capital spending).
From Dyne Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.